A rare case of pseudomyxoma peritonei caused by borderline mucinous tumor arising from primary mature cystic ovarian teratoma

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by diffuse intraperitoneal mucinous spread originating from mucinous neoplasms. The most common cause of PMP is a mucinous epithelial tumor of the appendix, but may also develop from other abdominal organs such as the ovaries, colon, and pancreas. Here, we describe the case of a patient with a prior history of appendectomy, in whom the appendix was easily excluded as the primary site of PMP. Previous studies have reported that only 3–8% of ovarian mucinous tumors may arise from mature cystic teratoma. In addition, borderline ovarian malignancies from mature cystic teratoma are not common, and the occurrence of PMPs from these borderline ovarian mucinous tumors is very rare. We report a rare case of PMP with clinicopathological features between PMP and borderline mucinous tumors arising in a mature cystic teratoma of the ovary.

Pseudomyxoma peritonei; Ovarian neoplasm; Adenocarcinoma; Mucinous

[1] Jacquemin G, Laloux P. Pseudomyxoma peritonei: review on a cluster of peritoneal mucinous diseases. Acta chirurgica Belgica. 2005; 105: 127–133.

[2] Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Advances in Surgery. 1996; 30: 233–280.

[3] Yan F, Shi F, Li X, Yu C, Lin Y, Li Y, et al. Clinicopathological characteristics of pseudomyxoma peritonei originated from ovaries. Cancer Management and Research. 2020; 12: 7569–7578.

[4] Talia KL, Parra-Herran C, McCluggage WG. Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach. Histopathology. 2022; 80: 255–278.

[5] Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. The American Journal of Surgical Pathology. 1995; 19: 1390–1408.

[6] Valasek MA, Pai RK. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Advances in Anatomic Pathology. 2018; 25: 38–60.

[7] Saluja M, Kenwright DN, Keating JP. Pseudomyxoma peritonei arising from a mucinous borderline ovarian tumour: case report and literature review. Australian and New Zealand Journal of Obstetrics and Gynaecol-ogy. 2010; 50: 399–403.

[8] Hwang JH, So K, Modi G, Lee JK, Lee NW, Lee KW, et al. Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei. International Journal of Gynecological Pathology. 2009; 28: 376–380.

[9] Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, et al. Pseudomyxoma peritonei of extra-appendiceal origin: a comparative study. Annals of Surgical Oncology. 2016; 23: 4222–4230.

[10] Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973; 31: 1031–1045.

[11] Bladt O, De Man R, Aerts R. Mucinous cystadenoma of the ovary. Journal of the Belgian Society of Radiology. 2004; 87: 118–119.

[12] Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. The American journal of surgical pathology. 1994; 18: 591–603.

[13] Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. The American Journal of Surgical Pathology. 1991; 15: 415–429.

[14] Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). Journal of Surgical Oncology. 2008; 98: 277–282.

[15] Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology. 2014; 109: 740–745.

[16] Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei: analysis of 519 patients. European Journal of Surgical Oncology. 2014; 40: 515–520.